Welcome to our dedicated page for Penumbra news (Ticker: $PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Penumbra's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Penumbra's position in the market.
Penumbra, Inc. reported strong financial results for the first quarter of 2024, with revenue reaching $278.7 million, a 15.4% increase over the previous year. The company's U.S. thrombectomy revenue saw a significant growth of 35.2%. The non-GAAP income from operations was $19.3 million, and adjusted EBITDA was $37.6 million with a margin of 13.5%. Penumbra's total revenue growth and U.S. thrombectomy revenue guidance for the full year 2024 are 16-20% and 27-30%, respectively. The company expects continued growth in revenue and gross margin expansion for the year.
Penumbra, Inc. (NYSE: PEN) will be presenting at the RBC Capital Markets Global Healthcare Conference on May 15, 2024. The webcast of the presentation will be available on the company's website for two weeks after the event.